查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447058

到 2030 年小分子標靶癌症治療市場預測：按類型、應用和地區分類的全球分析

Small Molecule Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球小分子標靶癌症治療市場規模將達825億美元，預計2030年將達到1,479億美元，預測期內年複合成長率為8.7%。

小分子藥物比高分子藥物更容易滲透細胞，並能有效抑制癌細胞生存所必需的蛋白質和酵素的活性。

小分子藥物是指製藥業的一個部分，專門開發和商業化專門針對癌細胞並使用小分子抑制其生長的藥物。這些治療方法透過抑制參與癌症生長、進展和轉移的特定分子發揮作用，與傳統化療相比，提供更精確、更有針對性的治療方法。

據FDA稱，Cetuximab單抗等單株抗體的半衰期（3.1至7.8天）比Gefitinib等小分子藥物的半衰期（48小時）長得多。

癌症發生率增加

不同人口和地區的癌症發生率不斷增加，增加了對有效治療方案的需求。透過特異性針對癌細胞中的分子變化，小分子標靶治療可以抑制癌細胞增殖或誘導細胞死亡，同時對健康細胞的傷害最小，為癌症治療提供了一種有前景的途徑。此外，化療等傳統治療方法通常會產生使人衰弱的副作用，從而增加了對更有針對性和毒性較小的治療方法的需求。

開發成本高

開發針對特定癌細胞的小分子藥物需要廣泛的研究、臨床試驗和監管核准，所有這些都需要高昂的成本。確定適當的分子標靶、設計化合物、最佳化功效和確保安全的複雜過程需要大量的財務投資。然而，嚴格的監管要求和漫長的核准時間進一步增加了整體開發成本。對於缺乏財務資源的中小型生技公司和新興企業來說，高成本是進入市場的主要障礙。

技術進步

高通量篩檢、分子建模和計算化學等最尖端科技能夠識別和設計小分子，從而提高針對癌症靶點的特異性和功效。分析技術的進步有助於準確表徵候選藥物並最佳化其藥物動力學和動態特性。此外，藥物輸送系統的創新，包括奈米技術和標靶藥物輸送，透過提高腫瘤滲透性和減少脫靶效應，提高了小分子藥物的治療指數。

有限的生物標記

生物標記是生物過程或治療反應的可測量指標，在識別適合標靶治療的患者方面發揮關鍵作用。針對某些癌症和標靶治療的生物標記的可用性通常是有限的。這種限制阻礙了準確選擇標靶治療最有效的患者，導致治療結果不佳並可能限制市場成長。因此，生物標記的缺乏限制了癌症標靶藥物的功效，並且還透過減少符合這些治療條件的患者數量來阻礙市場成長。

COVID-19 的影響：

醫療保健服務和資源的中斷轉移了癌症治療的注意力和資源，導致診斷和治療啟動的延遲。新的小分子標靶療法的臨床試驗面臨中斷或推遲，阻礙了新藥的開發和核准。供應鏈中斷和行動限制進一步影響了現有治療藥物的製造和分銷，導致患者獲得治療的短缺和延誤。然而，醫療保健系統和患者的經濟負擔也影響了這些治療方法的負擔能力和利用。

蛋白酪氨酸激酶抑制劑領域預計在預測期內規模最大

由於其獨特的作用機制和針對各種癌症類型的功效，蛋白酪氨酸激酶抑制劑預計將在預測期內獲得最大佔有率。蛋白酪氨酸激酶抑制劑部分將在預測期內佔據最大的市場佔有率，因為這些抑制劑針對特定的蛋白酪氨酸激酶，這些酶在涉及癌細胞生長和增殖的訊號傳導途徑中發揮重要作用。蛋白酪氨酸激酶抑制劑的精確標靶性可最大程度地減少對健康細胞的損害，從而比傳統化療產生更少的副作用。此外，療效提高、毒性降低的新型 TKI 的市場開拓擴大了各種癌症患者的治療選擇，進一步推動了市場成長。

預計黑色素瘤細分市場在預測期內年複合成長率最高

預計黑色素瘤領域在預測期內將出現顯著成長。黑色素瘤是一種皮膚癌，其發生率在全球範圍內顯著增加，推動了對有效治療方法的需求。小分子標靶治療透過特異性針對參與癌症生長和進展的分子來提高對抗黑色素瘤的精確度，與傳統治療方法。此外，研究進展導致新型小分子藥物的開發，這些藥物針對黑色素瘤中涉及的特定基因突變和途徑，擴大了患者的治療選擇。這些因素正在推動該細分市場的成長。

比例最高的地區：

隨著癌症治療擴大根據患者獨特的分子特徵進行客製化，預計亞太地區將佔據最大的市場佔有率，這被認為是個人化醫療。針對癌症患者的特定小分子可能會實現更個人化和精確的治療計劃，並考慮到每個病例的特殊性。隨著基因組序列測定技術的進步，找到與特定癌症相關的罕見遺傳異常和生物標記將變得更加容易。此外，該領域豐富的遺傳資料使製藥公司能夠開發與特定基因譜相關的高度標靶化的藥物，從而提高治療效果和精確度。

年複合成長率最高的地區：

隨著醫療保健提供者更加了解癌症治療中標標靶治療的益處和有效性，並更有可能向患者推薦這些療法，預計亞太地區在預測期內將出現盈利成長。這種認知將導致更多地採用特異性針對癌細胞的小分子標靶療法，同時最大限度地減少對健康細胞的損害。此外，該地區的醫療保健提供者隨時了解支持標靶治療的最新進展和臨床證據，使他們能夠識別適合這些治療的患者並根據個人需求量身定做治療方法。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球小分子標靶癌症治療市場：依類型

  • 蛋白酪氨酸激酶抑制劑
  • 小分子藥物偶聯物
  • 其他類型

第6章 全球小分子標靶癌症治療市場：依應用分類

  • 乳癌
  • 多發性骨髓瘤
  • 黑色素瘤
  • 淋巴瘤
  • 攝護腺癌
  • 其他用途

第7章全球小分子標靶癌症治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bayer HealthCare AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cytokinetics Inc
  • Genentech
  • GlaxoSmithKline plc
  • Hospira Inc
  • Novartis
Product Code: SMRC25319

According to Stratistics MRC, the Global Small Molecule Targeted Cancer Therapy Market is accounted for $82.5 billion in 2023 and is expected to reach $147.9 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Small molecule drugs can penetrate cells more easily than larger molecules, allowing them to effectively inhibit the activity of proteins and enzymes critical for cancer cell survival.

It refers to the segment of the pharmaceutical industry dedicated to developing and commercializing drugs specifically designed to target and inhibit the growth of cancer cells through small molecules. These therapies work by interfering with specific molecules involved in the growth, progression, and spread of cancer, thereby offering more precise and targeted treatment options compared to traditional chemotherapy.

According to the FDA, the half life of monoclonal antibodies like cetuximab (3.1-7.8 days) is much longer than those of small-molecule agents like gefitinib (48 hours).

Market Dynamics:

Driver:

Increasing incidence of cancer

With cancer rates on the rise across various demographics and geographies, there is a growing demand for effective treatment options. Small molecule targeted therapies offer promising avenues for cancer treatment by specifically targeting molecular alterations in cancer cells, thereby inhibiting their growth or inducing cell death with minimal harm to healthy cells. Additionally, as traditional treatments like chemotherapy often come with debilitating side effects, the demand for more targeted and less toxic therapies is increasing.

Restraint:

High development costs

Developing small molecule drugs tailored to target specific cancer cells involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. The intricate process of identifying suitable molecular targets, designing compounds, optimizing their efficacy, and ensuring their safety demands substantial financial investments. However, the rigorous regulatory requirements and lengthy approval timelines further escalate the overall development costs. For smaller biotechnology companies or startups with limited financial resources, these high costs present a considerable barrier to entry into the market.

Opportunity:

Technological advancements

Cutting-edge technologies such as high-throughput screening, molecular modeling, and computational chemistry enable the identification and design of small molecules with enhanced specificity and efficacy against cancer targets. Advances in analytical techniques facilitate the precise characterization of drug candidates, optimizing their pharmacokinetic and pharmacodynamic properties. Moreover, innovations in drug delivery systems, including nanotechnology and targeted drug delivery, enhance the therapeutic index of small molecule drugs by improving their tumor penetration and reducing off-target effects.

Threat:

Limited biomarkers

Biomarkers, which are measurable indicators of biological processes or responses to treatment, play a crucial role in identifying suitable patients for targeted therapies. The availability of biomarkers specific to certain types of cancer or targeted therapies is often limited. This limitation hampers the precise selection of patients who would benefit most from small molecule targeted therapies, leading to suboptimal treatment outcomes and potentially limiting market growth. Therefore, the lack of biomarkers limits the efficacy of targeted cancer medicines and also prevents market growth by reducing the number of patients that are eligible for these treatments.

Covid-19 Impact:

Disruptions in healthcare services and resources diverted attention and resources away from cancer treatment, leading to delays in diagnosis and initiation of therapy. Clinical trials for new small molecule targeted therapies faced interruptions or postponements, hindering the development and approval of new drugs. Supply chain disruptions and restrictions on movement further affected the manufacturing and distribution of existing therapies, causing shortages and delays in treatment access for patients. However, financial strains on healthcare systems and patients also impacted the affordability and utilization of these therapies.

The tyrosine kinase inhibitors segment is expected to be the largest during the forecast period

Due to their unique mechanism of action and effectiveness in treating various types of cancers. These inhibitors target specific tyrosine kinases, which are enzymes that play a crucial role in the signaling pathways involved in cancer cell growth and proliferation, Tyrosine Kinase Inhibitors segment is expected to hold the largest share during the projection period. Their precision targeting minimizes damage to healthy cells, leading to fewer adverse effects compared to traditional chemotherapy. Additionally, the development of novel TKIs with improved efficacy and reduced toxicity profiles has expanded treatment options for patients with different types of cancers, further driving market growth.

The melanoma segment is expected to have the highest CAGR during the forecast period

Melanoma segment is estimated to have the considerable growth over the forecast period. Melanoma, a type of skin cancer, has seen a substantial rise in incidence globally, driving the demand for effective treatments. Small molecule targeted therapies offer precision in combating melanoma by specifically targeting molecules involved in cancer growth and progression, resulting in enhanced efficacy and reduced side effects compared to traditional treatments. Additionally, advancements in research have led to the development of novel small molecule drugs tailored to target specific genetic mutations and pathways implicated in melanoma, expanding the therapeutic options available to patients. These elements are enhancing the segmental growth.

Region with largest share:

Because treatments for cancer are increasingly being customized to a patient's unique molecular profile, a phenomenon recognized as personalized medicine, the Asia Pacific region is expected to hold the largest share of the market during the projected period. Targeting specific small molecules in cancer patients may allow for more individualized and accurate treatment plans that take into account the particulars of their individual cases. As genome sequencing technology develops, it becomes simpler to find uncommon genetic anomalies and biomarkers connected to certain cancers. Furthermore, pharmaceutical companies can create highly targeted medications that are linked to certain genetic profiles due to the wealth of genetic data available in the area, improving treatment efficacy and precision.

Region with highest CAGR:

As healthcare providers become more knowledgeable about the benefits and effectiveness of targeted therapy in cancer treatment, they are more likely to recommend it to their patients, Asia Pacific region is estimated to witness profitable growth throughout the extrapolated period. This awareness leads to greater adoption of small molecule targeted therapies, which are designed to specifically target cancer cells while minimizing damage to healthy cells. Additionally, as healthcare providers in the region stay updated on the latest advancements and clinical evidence supporting targeted therapies, they become better equipped to identify suitable patients for these treatments and tailor therapy regimens to individual needs.

Key players in the market

Some of the key players in Small Molecule Targeted Cancer Therapy market include Abbott Laboratories, Amgen, AstraZeneca, Bayer HealthCare AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cytokinetics Inc, Genentech, GlaxoSmithKline plc, Hospira Inc and Novartis.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In February 2024, Erasca, Inc., a precision oncology company, has entered into clinical trial collaboration and supply agreements with pharmaceutical giant Novartis to advance the development of a new cancer treatment.

Types Covered:

  • Tyrosine Kinase Inhibitors
  • Small Molecule Drug Conjugates
  • Other Types

Applications Covered:

  • Breast Cancer
  • Multiple Myeloma
  • Melanoma
  • Lymphoma
  • Prostate Cancer
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Targeted Cancer Therapy Market, By Type

  • 5.1 Introduction
  • 5.2 Tyrosine Kinase Inhibitors
  • 5.3 Small Molecule Drug Conjugates
  • 5.4 Other Types

6 Global Small Molecule Targeted Cancer Therapy Market, By Application

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Multiple Myeloma
  • 6.4 Melanoma
  • 6.5 Lymphoma
  • 6.6 Prostate Cancer
  • 6.7 Other Applications

7 Global Small Molecule Targeted Cancer Therapy Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abbott Laboratories
  • 9.2 Amgen
  • 9.3 AstraZeneca
  • 9.4 Bayer HealthCare AG
  • 9.5 Boehringer Ingelheim GmbH
  • 9.6 Bristol-Myers Squibb
  • 9.7 Cytokinetics Inc
  • 9.8 Genentech
  • 9.9 GlaxoSmithKline plc
  • 9.10 Hospira Inc
  • 9.11 Novartis

List of Tables

  • Table 1 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 4 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 5 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 7 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 8 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 9 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 10 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 11 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 12 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 13 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 14 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 15 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 16 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 17 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 18 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 20 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 21 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 22 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 23 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 24 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 27 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 28 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 29 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 30 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 32 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 33 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 34 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 35 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 36 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 39 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 40 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 41 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 42 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 44 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 45 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 46 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 47 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 48 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 52 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 53 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 54 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 55 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 56 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 57 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 58 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 59 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 60 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 63 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 64 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 65 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 66 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 67 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 68 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 69 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 70 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 71 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 72 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)